Salsalate
 | |
| Clinical data | |
|---|---|
| Trade names | Disalcid, Salflex |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682880 |
| Pregnancy category |
|
| ATC code | N02BA06 (WHO) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
552-94-3  |
| PubChem (CID) | 5161 |
| DrugBank |
DB01399 |
| ChemSpider |
4977  |
| UNII |
V9MO595C9I |
| KEGG |
D00428 |
| ChEBI |
CHEBI:9014 |
| Chemical and physical data | |
| Formula | C14H10O5 |
| Molar mass | 258.23 g/mol |
| (what is this?) (verify) | |
Salsalate is a medication that belongs to the salicylate and non-steroidal anti-inflammatory drug (NSAID) classes. Relative to other NSAIDs, salsalate has a weak inhibitory effect on the cyclooxygenase enzyme and decreases the production of several proinflammatory chemical signals such as interleukin-6, TNF-alpha, and C-reactive protein.[1] The mechanism through which salsalate is thought to reduce the production of these inflammatory chemical signals is through the inhibition of IκB kinase resulting in decreased action of NF-κB genes.[1][2][3] This mechanism is thought to be responsible for salsalate's insulin-sensitizing and blood sugar lowering properties.[2] Salsalate is the generic name of a prescription drug marketed under the brandnames Mono-Gesic, Salflex, Disalcid, and Salsitab. Other generic and brand name formulations may be available.[4]
Medical uses
Salsalate may be used for inflammatory disorders such as rheumatoid arthritis or noninflammatory disorders such as osteoarthritis.[1][5]
Safety
The risk of bleeding is a common concern with use of the NSAID class of medications. However, the bleeding risk associated with salsalate is lower than that associated with aspirin use.[2]
Research
Salsalate has been proposed for the prevention and treatment of type 2 diabetes mellitus due to its ability to lower insulin resistance associated with inflammation and may be useful in prediabetes.[1] However, the use of salsalate to prevent the progression from prediabetes to type 2 diabetes mellitus has received limited study.[1]
History
Salsalate had been suggested as possible treatment for diabetes as early as 1876.[1][6][7]
Synthesis
References
- 1 2 3 4 5 6 Anderson K, Wherle L, Park M, Nelson K, Nguyen L (June 2014). "Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies". Am Health Drug Benefits. 7 (4): 231–5. PMC 4105730
. PMID 25126374. - 1 2 3 Esser N, Paquot N, Scheen AJ (March 2015). "Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease". Exp Opin Investig Drugs (Review). 24 (3): 283–307. doi:10.1517/13543784.2015.974804. PMID 25345753.
- ↑ Ridker PM, Lüscher TF (July 2014). "Anti-inflammatory therapies for cardiovascular disease". Eur Heart Journal. 35 (27): 1782–91. doi:10.1093/eurheartj/ehu203. PMC 4155455. PMID 24864079.
- ↑ drugs.com Salsalate entry
- ↑ Hardie DG (July 2013). "AMPK: a target for drugs and natural products with effects on both diabetes and cancer". Diabetes. 62 (7): 2164–72. doi:10.2337/db13-0368. PMC 3712072. PMID 23801715.
- ↑ Powell, Kendall (May 31, 2007). "The Two Faces of Fat". Nature. 447 (7144): 525–7. doi:10.1038/447525a. PMID 17538594.
- ↑ Ebstein, W (1876). "Zur therapie des diabetes mellitus, insbesondere uber die anwendung des salicylsauren natron bei demselben". Berliner Klinische Wochenschrift. 13: 337–340.
- ↑ Cavallito, Chester J.; Buck, Johannes S. (1943). "Synthesis of Phenolic Acid Esters. I. Depsides1". Journal of the American Chemical Society. 65 (11): 2140. doi:10.1021/ja01251a034.
- ↑ Baker, Wilson; Ollis, W. D.; Zealley, T. S. (1951). "42. Eight- and higher-membered ring compounds. Part II. Di-, tri-, tetra-, and hexa-salicylides". Journal of the Chemical Society (Resumed): 201. doi:10.1039/JR9510000201.